Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The pharmaceutical company said Thursday the drug did not meet its primary endpoint of sustained remission after 52 weeks of use in a phase three trial. Novartis said it will complete a full ...

The forum came at time when there appears to be little health messaging at the federal level.

Vamos Racquets will open in East Hanover with padel, pickleball, fitness, coworking and more at the former Novartis campus ...

ProFound Therapeutics, a company pioneering the expanded human proteome to develop medicines, has announced a four-year ...

Novartis AG Sponsored ADR (NVS) is currently at $120.93, up $0.92 or 0.77% --Would be new all-time closing high (Based on available data back to Dec. 24, 1996) --Would be the first record close since ...

Organizations that delay systematic AI deployment risk being left behind by competitors who have already mastered the transition from experimentation to execution.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Novartis ...

Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase inhibitor for the adjuvant treatment of adults with stage II-III early breast ...